Myasthenia gravis and multiple sclerosis: A review of the ocular manifestations

Insight - Journal of the American Society of Ophthalmic Registered Nurses

Volumn 31, Issue 3, 2006, Pages 19-22

  Costello, Fiona ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EYE DISEASE; HUMAN; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; PROGNOSIS; REVIEW; RISK FACTOR;

EYE DISEASES; HUMANS; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; PROGNOSIS; RISK FACTORS;

EID: 33751206838     PISSN: 1060135X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Barton JS, Fouladvand M. Ocular aspects of myasthenia gravis. Sem Neurol. 2000;20:7-20.
2. Awwad S. Myasthenia gravis. eMedicine. http://emedicine.com/oph/ topic263.htm.
3. Newton, E. Myasthenia Gravis. http://www.emedicine.com/EMERG/topic325.htm
4. Hamilton, SR. Myasthenia Gravis and Ocular Myopathies. Neuro-Ophthalmology: The Practical Guide 2005, 304-309
5. Hickman SJ, Dalton CM, Miller DH. Management of acute optic neuritis. Lancet 2002;360:1953-1962.
6. Kaufman DI, Trobe JD, Eggenberger ER. Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Neurology. 2000;54:2039-2044.
7. Soderstrom M, Ya-Ping J, Hillert J. Optic neuritis prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology. 1998;50:708-714.
8. Beck RW, Cleary PA, Anderson MM. A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med. 1992;326:581-588.
9. Optic Neuritis Study Group. The clinical profile of optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1991;109:1673-1678.
10. Eggenberger ER. Inflammatory optic neuropathies. Ophthalmol Clin North Am. 2001;14:73-82.
11. Soderstrom M. Optic neuritis and multiple sclerosis. Acta Ophthalmol Scand. 2001;79:223-227.
12. Lee AG, Brazis PW. Clinical Pathways in Neuro-Ophthalmology: An Evidence- Based Approach. 2nd ed. New York: Thieme Medical Publishers; 2003.
13. Purvin V. Optic neuropathies for the neurologist. Sem Neurol. 2000;20:97-110.
14. Fay AM, Kane S, Kazim M. Magnetic resonance imaging of optic perineuritis. J Ophthalmol. 1997;17:247-249.
15. Cree BAC, Goodin DS, Hauser SL. Neuromyelitis optica. Sem Neurol. 2002;22:105-122.
16. Van Stavern GP. Management of optic neuritis and multiple sclerosis. Curr Opin Ophthalmol. 2001;12:400-407.
17. Jacobs LD, Beck RW, Simon JH. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000;343:898-904.
18. Comi G, Filippi M, Barkof F. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 2001;357:1576-1582.
19. Balcer LJ. Evidence-based neuro-ophthalmology: advances in treatment. Curr Opin Ophthalmol. 2001;12:387-392.
20. Miller D, Barkfof F, Montalban X. Clinically isolated syndromes suggestive of multiple sclerosis, part 1: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005;4:281-288.
21. Optic Neuritis Study Group. High and low risk profiles for the development of multiple sclerosis within 10 years after optic neuritis. Arch Ophthalmol. 2003;121:944-949.
22. Miller D, Barkof F, Montalban A et al. Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes and management. Lancet Neurol 2005;4:341-48
23. Kappos L, Polman CH, Freedman MS et al. Treatment with Interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1-1
24. Frohman EM, Frohman TC, Zee DS et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005;4:111-21
25. Lee AG. Multiple sclerosis: eMedicine. http://www.emedicine.com/oph/ topic179/htm